LENZ Therapeutics, Inc. (LENZ) Stock Profile — Insider Trades & Financials

Revenue$1.6M

Net Income-$35.9M

EPS$-1.65

Market Cap$296.3M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Evert Schimmelpennink

CEO & Executive Director

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Founded: 2019
Employees: 152
Headquarters: Solana Beach, California, United States
Website

⚡

Core Efficiency

ROE?

-12.62%

ROA?

-11.74%

D/E Ratio?

0.08

Op. Margin?

-2422.10%

📊

Profitability Ratios

Net Margin?

-2260.45%

Loading company sections...

LENZ Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness